Current oncology therapies, particularly in late-stage disease, are often limited in their effectiveness, and as such, there is a large un-met need in this patient population. At Carrick Therapeutics, our science focuses on developing novel therapies using agents targeting key oncogenic pathways. We believe our programs will fill the gaps in current therapeutic options for patients.
With in-licensing as a cornerstone to our strategy, we have the freedom to follow the best science maximising the ability to develop successful therapies for cancer.
We are focused on developing innovative agents which have the potential to be both first- and best-in-class.
Our strategy, is to address gaps in existing therapies for cancer. Our science focuses on developing candidates to complement, existing therapies primarily for advanced and aggressive cancers.
Our clinical-stage programs are intended to complement existing oncology therapies and will be used in combination to extend the use of current drugs and/or target the acquired resistance to these agents. In addition, Carrick's programs, each have potential applications across multiple types of cancer thereby generating a portfolio of indications for each asset.
Explore posters and publications about our science.
View posters & publications